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Abstract 
Background: Cancer of unknown primary is the fourth most common cause of cancer 
death in the United Kingdom. National guidance in 2010 recommended the establishment 
of a dedicated unknown primary team to facilitate targeted investigation and symptom 
control. A service development project was undertaken to identify those affected by 
malignancy of unknown origin and institute a pathway for coordinating their care led by a 
palliative physician.  
Aim: To describe the patient population and illness trajectory and to assess the effect of 
the new pathway on the clinical outcomes.  
Design: A retrospective and prospective comparative case notes survey to identify the 
pre- and post-pathway population. 
Setting/participants: This took place in secondary care. Inclusion criteria were patients 
with metastatic disease with no known primary; exclusion criteria were where the site of 
metastasis was so suggestive of a primary that it would be managed as per that disease 
process. 88 patients were included. 
Results: Mean age was 72.5 years. The mean survival time from presentation was 81.8 
days. There was no difference pre or during pathway implementation in age, performance 
status or survival time. There was no reduction in the numbers referred for tumour 
directed therapy. There was a non-statistically significant reduction in the number who 
died in hospital during the pathway implementation.   
Conclusions: This study suggests having a metastatic malignancy of unknown primary 
origin service led by a palliative physician does not reduce the number referred for 
tumour directed therapy. It also adds evidence of the poor prognosis and thus the need for 
early palliative care input. 
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1.Introduction 
Carcinoma of Unknown Primary is the fourth most common cause of cancer death,with 
an incidence stated to be from 3% to 5% of all malignancies [1,2,3]. Up to eighty per 
cent have unfavourable prognostic features[4] and, in this subset, a meta-analysis has 
not shown chemotherapy to lengthen survival[5]. While some studies have described 
the management of those who end up with a diagnosis of Cancer of Unknown Primary 
Origin [7-9] there have been no studies that describe the early management of the larger 
group that who present with Metastatic Malignancy of Undefined Primary origin[10]. 
Until recently this patient group had not had care and management overseen by any one 
specific team. National Institute for Health and care excellence (NICE) guidance on 
diagnosis and management of metastatic malignant disease of unknown primary 
origin[1] recommended the establishment of a dedicated unknown primary team 
(including oncologist, palliative care physician and specialist nurse) in hospitals with a 
cancer unit to provide equity with site-specific cancers. The aim of a specialist team is 
to ensure early symptom control, individualised support and information which is to be 
delivered alongside targeted investigations and appropriate treatment. The importance 
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of supportive and palliative care within this process suggests the palliative physician as 
a suitable person to be the lead clinician. 
1.1 Rationale for service development 
A small scale audit of patients with cancer of unknown primary was conducted at a 
district general hospital. This indicated a similar situation to that reported in the wider 
literature. No system existed to identify these patients as a distinct group, but 
retrospective audit showed that 11 of 14 patients reviewed had died in the hospital, with 
an average length of stay of 21.5 days. Repeating of tests was common, suggesting an 
important burden at the end of life. Specialist palliative care involvement conferred 
benefit, but was sometimes a late consideration[6]. 
Contemporary with the devising of the NICE Guidance a service development was 
planned at the district general hospital. This initiative aimed to identify patients 
presenting with metastatic malignancy of undefined primary origin, and institute a new 
pathway for co-ordinating their care, with the palliative physician as lead clinician. This 
development would provide more data about patients who present in this way, assess 
whether a palliative care led service would work, and document the definitive 
treatments and outcomes for patients.  
1.2 Designing the Intervention: a new pathway approach 
A multidisciplinary Unknown Primary team was set up consisting of a palliative 
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physician (lead clinician), an oncologist with interest in cancer of unknown primary 
origin, a histo-pathologist, a radiologist and specialist palliative care nurses. In-patients 
referred to the Unknown Primary team were to be reviewed within one working day on 
the ward. Patients were discussed at a weekly Unknown Primary MDT meeting which 
included an upper GI surgeon and physician in addition to the core team.  Additional 
discussions took place between core team members to expedite decisions and facilitate 
patient flow. The intervention aimed to provide individualised patient care; assessment 
of history, family history and risk factors; and review of fitness for potential future 
Tumour Directed Treatment (TDT) with assessment of patients wishes. Alongside this, 
the intervention ensured attention to early symptom control, maximising quality of life 
and ensuring on-going support and information.   
The main barrier to developing the service was that this was not seen by commissioners 
or managers as "new business" for the hospital. These patients were being managed in 
various parts of the hospital already so implementing a service which co-ordinated their 
care more effectively and provided additional support was not going to generate extra 
income for the hospital. It was therefore difficult to identify additional resource to 
develop the service. The funding that was initially identified was partial and non 
recurrent out of charitable funds but much of the service was developed through 
goodwill. Only when the service was established and shown to be beneficial was 
recurrent funding identified. 
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 Sh
eff
iel
d]
, [
Pe
ter
 B
ath
] a
t 0
2:0
5 0
3 J
an
ua
ry
 20
18
 
A
cc
ep
te
d 
M
an
us
cr
ip
t
Implementation of a metastatic malignancy of unknown primary origin service led by a 
palliative physician  
7 
 
2. Evaluation study 
An evaluation study was set up with the aim of assessing the clinical and service quality 
outcomes, and patient experiences before and following the implementation of the 
pathway. This was granted ethical approval from the East Midlands- Leicester Research 
Ethics Committee (reference number 08/H0406/178).  
The main objective was to describe this patient population, service need and subsequent 
illness trajectory using a pragmatic clinical approach based on mode of presentation, 
rather than criteria based on final confirmed diagnosis.    
2.1 Inclusion criteria  
All patients who had presumed or probable metastatic disease with no known (or highly 
suspected) primary disease were included. In addition, we included patients for whom 
the suspected primary disease had been excluded, who would no longer be appropriately 
managed by the site-specific pathway multi-disciplinary team. 
2.2 Exclusion criteria  
Where the site and histology of lymph node disease is so indicative of a primary site 
that it would be managed as per that disease process even when the primary is not 
discovered, then direct referral to the site specific MDT is the norm.  
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3. Method 
The study was a multi method research study located in a district general hospital, 
Chesterfield Royal Hospital NHS Foundation Trust, with a catchment population of 
375,000) over two six-month periods (November 2008-April 2009 and April 2010-
October 2010). This paper reports on a retrospective and prospective comparative cross-
sectional survey of data from patients clinical records before and during the 
intervention. This was one element of a larger study.  
A method of identifying patients with metastatic malignancy of undefined primary 
origin(MUO) was devised. Pre-intervention this was conducted retrospectively and 
made use of site-specific MDT meetings, radiological reports marked serious or 
unexpected findings, palliative care patient database, and in-patient admission coding. 
During the intervention phase patients with metastatic malignancy of undefined primary 
origin were identified prospectively: referred by other clinicians to the pathway (as in-
patients or out-patients), or for discussion at the Unknown Primary MDT, or identified 
by the team as suitable for the pathway from their palliative care referrals.  To ensure 
comparability and to evaluate the referral rate, patients were also identified 
retrospectively using the pre-intervention process and included in the intervention group 
for the purpose of analysis. 
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3.1 Outcome Measures 
The primary outcome measure was the time from referral to instigation of definitive 
treatment. 
The date of referral was the point where a secondary care physician was first alerted to 
the presumed or probable presence of metastatic disease that required investigation. 
Instigation of definitive treatment was defined as the date the patient received their 
definitive treatment, or the date when this decision was made, whichever was the latest.  
Secondary outcome measures included: the number of patients referred to, offered and 
subsequently accepting oncological treatment, survival time and place of death.  
3.2 Data analysis 
Kaplan Meier survival analyses were undertaken to compare the mean survival times of 
groups of patients.  The mean time and 95% confidence intervals (CI) were calculated 
between date of referral and the institution of definitive treatment for the two groups of 
patients, pre and post implementation of the intervention. Comparison was made of 
secondary outcome measures in the two groups of patients. Analyses were undertaken 
using IBM Statistical Package for the Social Sciences (SPSS, also know as PASW) 
versions 19 and 22.  
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4. Results  
4.1 The process of instituting the intervention 
The initiation of the pathway was more staggered than anticipated; initially the service 
consisted solely of an Unknown Primary MDT meeting and then in-patient reviews 
followed. A primary investigation out-patient clinic was established, with a maximum 
two-week wait, accepting referrals from both primary care and hospital. Hospital 
procedures and systems led to delays in establishing this clinic until after the end of the 
second data collection phase. The service was advertised through cascade, word of 
mouth and through education meetings.  
A total of 88 patients were identified in the two study periods, pre interventions and 
during pathway implementation. The mean age of participants was 72.51 years old 
(range 44-98; SD = 11.21; median = 75). Forty-eight patients were female (54.5%) and 
40 were male (45.5%).  
4.2 Performance status 
The ECOG (Eastern Cooperative Oncology Group)performance status scale was used 
[11]. Twenty patients (22.7%) had a performance status of 0-1, 15 patients (17.0%) had 
a performance status of 2 and 52 patients (59.1%) had a performance status of 3-4. 
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4.3 Survival times 
By 2
nd
 April 2015 85 of the 88 patients had died.  The mean survival time was 81.79 
days (95% CI = 60.33, 103.25). Overall, the mean time from referral to 
death/censorship was 180.45 days (95% CI = 106.34, 272.75; median = 44; n = 88). 
Figure 1 shows survival curves for those who had the primary site of the malignancy 
identified versus those who remained as Unknown Primary. The mean survival of 
those with an identified primary site was 152.8 days (95% CI =87.7, 217.97; 
median=65), whereas those who were unknown it was 85.3 days (95% CI=50.9, 119.7; 
median=28).  
Figure 2 compares those who were referred for tumour directed therapy versus those 
who were not. The mean survival for those in the treatment group was 363 days (95% 
CI=172.34, 553.98; median = 130) versus 52 days (CI=29.17, 75.43; median = 26) in 
the supportive care only group. It should be noted that not all those who were referred 
received treatment.  
4.4 Referrals to specialist palliative care 
Forty-three patients (48.9%) had a final diagnosis of cancer of unknown primary (or 
MUO). Referral to specialist palliative care could come about either because specialist 
palliative care needs were already recognised in a patients care, or because the newly 
introduced system prompted review by the palliative care physician. 
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4.4 Tumour-directed treatment (TDT) 
Forty patients (46%) were not considered suitable for referral for TDT and eight (9%) 
died before a decision on referral could be made. One person declined any further 
investigation or treatment. Thirty-nine people (44%) were referred for consideration of 
TDT. Of these 39, twenty-three patients had TDT as planned or with modifications, 
seven patients had tumour-directed treatment planned but were too ill for it to begin, 
and six patients commenced TDT, but then was stopped because they became too ill. Of 
the remaining three: one was offered treatment, but declined; one had treatment held in 
readiness but not given; and one, it was decided not to attempt treatment.  
Of the 23 patients who had treatment as planned or with modifications; 8 had 
radiotherapy; 7 chemotherapy; 3 a combination of radiotherapy and chemotherapy; 2 
had surgery; 1 endocrine treatment; one a combination of surgery and radiotherapy; and 
one a combination of surgery and chemotherapy. Of the six who began treatment, but 
had to stop because they were too ill, 5 had chemotherapy and 1 had radiotherapy. 
4.5 Site or sites of final diagnosis 
Forty-three patients (48.9%) had a final diagnosis of cancer of unknown primary, and 
45 patients (51.1%) had a final diagnosis of site-specific cancer or haematological 
malignancy. Table 1 shows the distribution of final diagnosis of the patients in the 
sample. 
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4.6 Place of death 
44.3% of patients died in the district general hospital (n=39), 19.3% died at the local 
hospice (n=17) and 22.3% died at home (n=20). Of the remainder, 3.4% (n=3) were still 
living at the time of review. Three died in a community hospital, and three in Cancer 
Centres and three were unknown.  
5. Comparison of the pre intervention and pathway implementation group. 
Data was collected on two cohorts of patients. The first related to the pre-pathway 
phase, and numbered 50. The second was from the pathway implementation phase, and 
numbered 38.  
In the implementation group, patients had experienced varying degrees of application of 
the new pathway approach. Of the 38 patients in this group:  8 (21%) were initiated on 
the pathway early in the diagnostic process; 8 (21%) were referred for discussion at the 
Unknown Primary MDT; 5 (13%) were referred to the Unknown Primary team late in 
the diagnostic process; 5 (13%) were picked up due to specialist palliative care referral; 
and 12 (32%) had no input from the Unknown Primary team.  
5.1 Age, gender and Performance status 
There was no statistically significant difference in the mean rank of the ages, gender or 
performance status of the pre-pathway patients compared with the pathway patients.  
5.2 Patient survival  
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There was no significant difference in terms of time from instigation of definitive 
treatment to death, and time from MUO referral to death between pre and pathway 
patients 
5.3 Primary outcome measure 
This had been designated as the time from referral to instigation of definitive treatment.  
There was no difference between pre pathway and pathwayimplementation patients in 
the mean rank of time from referral to instigation of definitive treatment. 
The range in the pre-pathway group was from 0 to 115 days, and the range in the 
pathway implementation group was from 0 to 74 days. This indicates that it is possible 
that the intervention shortens the pathway of those who wait the longest for definitive 
treatment. [Figure 3] 
5.4 Secondary outcome measures 
Twenty two of the pre-pathway patients (44%) were referred for TDT compared with 18 
of the pathway patients (47.4%). For 23 (46%) patients in the pre-pathway group 
referral was not considered suitable; and for 17 (44.8%) patients in the pathway group 
referral was not considered suitable. Five patients in the pre-pathway group (10%), and 
3 (7.9%) in the pathway implementation group died before a decision on referral could 
be made. 
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Fourteen of the pre-pathway patients (28.0%) and nine of the pathway patients (23.7%) 
had TDT as planned or with modifications. One of the pre-pathway patients (2.0%), and 
six of the pathway patients (15.8%) had TDT planned but it was not begun because they 
were too ill. Four of the pre-pathway patients (8.0%) and two of the pathway patients 
(5.3%) commenced TDT but it was stopped because they were too ill. 
It appears from this that using a pathway approach with the palliative care physician as 
lead clinician has not resulted in fewer referrals for tumour-directed treatment. The 
small proportions in both groups who actually complete such treatment, and the 
numbers who die before a decision on referral can be made, underline the extent of 
illness, and the poor prognosis for the majority of patients who present in this way. 
5.5 Final diagnosis 
There was no significant difference between the pre-pathway patients and the pathway 
patients in terms of the final diagnosis (Ȥ2 =0.00; df = 1; p=1.00). Of the 50 pre-pathway 
patients, 26 patients (52.0%) had a primary site identified and 24 patients (48.0%) had a 
final diagnosis of unknown primary. Of the 38 pre-pathway patients, 19 patients (50%) 
had the primary site identified and 19 patients (50%) had a final diagnosis of unknown 
primary. 
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5.6 Place of death 
We speculated that a death in the district general hospital might be a proxy for an 
incomplete resolution to the investigatory period. The grounds for this are that in those 
cases where care reached a point of resolution, patients would be discharged home, or 
referred to tertiary care. There was a difference between patients who died in the pre-
pathway group and the pathway group in whether they died in the district general 
hospital or elsewhere, although this did not reach statistical significance (Ȥ2=3.255; 
df=1; p=0.071).  Of the 48 pre-pathway patients who died, 27 died in the district general 
hospital (56.3%), whereas only 12 of the 37 pathway patie ts who had died (32.4%) 
died in the district general hospital.  
More people died at home in the pathway group: 7 (14.6%) people in the pre-pathway 
group and 13 (35.1%) people in the pathway group. Numbers are small however, and 
could have arisen due to chance. Of the pre-pathway group, 30 died in hospital (60%), 
and of the pathway group, 14 died in hospital (37%). Of the 50 pre-pathway patients, 10 
died in a hospice (20%), and of the 38 pathway patients, a similar proportion, 7 (18%), 
died in a hospice.   
6. Discussion 
Patients who presented to the hospital with MUO tended to be older (median age 75) 
with the majority having a poor performance status. They mostly have a poor prognosis, 
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as indicated by the median time from presentation to death which was 40 days. This 
cross-sectional study found approximately twice as many patients required palliative 
medicine referral (86.3%) compared to oncological or tumour-directed treatment 
referral (44.3%). Only around a quarter of patients (26.1%) completed planned tumour-
directed treatment.  Additionally, our data illuminated a number of issues concerning 
the current systems of recording, notably inconsistencies in coding, an issue also 
highlighted in NICE guidance. 
The development of the Unknown Primary team and pathway, led by a palliative 
medicine clinician did not appear to reduce the mean rank time from presentation with 
MUO to definitive treatment but there is some indication it may curtail the longest 
investigatory periods. No significant difference was seen following the intervention in 
the proportion of patients who had a primary site identified (50%), nor in survival time. 
There is some indication that instituting a pathway for managing MUO in a district 
general hospital has the potential to contain the length of time taken for investigation 
and increase the proportion of those patients who are discharged or transferred before 
death. 
This study describes a population of patients presenting with MUO and a potential 
method of implementing NICE guidance on referral pathways and management of these 
complex patients. The findings need to be interpreted with caution because this small 
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study was limited to one district general hospital. We were not able to realise fully the 
intended pre and post design, as the intervention cohort had variable exposure to the 
planned intervention, which took time to be fully embedded. This may have blunted 
some of the effect. Furthermore, the pre-intervention group may have been subject to 
the Hawthorn effect, as the rationale for the development of the Unknown Primary 
service, its approach and working methods were being discussed within the hospital 
during this period. 
This study demonstrates the practicality and acceptability of introducing a pathway 
approach, establishing a team, and developing working practices, including a dedicated 
out-patient clinic within a district general hospital, for the management of care of 
patients presenting with MUO. 
The study supports the case for timely assessment of what, if any, tumour-directed 
therapy the patient could tolerat , in conjunction with the patients wishes regarding 
further investigations and treatment.  Most of these patients have a poor prognosis and 
will be referred for specialist palliative care. Having a lead physician with a palliative 
medicine background could potentially improve continuity of care and symptom control 
for this complex group of patients. Importantly, this research does not support fears that 
early specialist palliative care involvement might decrease oncology referral, or reduce 
the likelihood of a final diagnosis being made. 
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The time necessary to fully establish the intervention, particularly the clinic should be 
noted, as should the need to ensure smooth processes for ensuring referral from primary 
care, and opportunities for early discharge with out-patient follow-up. Another 
important lesson was the need for discussions outside of the formal MDT meetings to 
expedite the process, and the invaluable nature of an interested radiologist and 
pathologist.  
We will review our findings in a further study with over a longer period to include a 
larger population now that the pathway approach has been fully implemented into the 
clinical service. The difference in deaths at home shown in our data would also bear 
fuller investigation to test if the intervention had some impact here.  
Conclusions 
This evaluation adds support to NICEs recommendation of the development of 
multidisciplinary teams to investigate and support people presenting with metastatic 
malignancy of unknown primary origin and makes the case for Palliative Medicine 
Physicians to be L ad Clinicians in these teams. 
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Table 1: Site of final diagnosis 
Final Diagnosis Frequency  % 
Carcinoma of Unknown Primary 43 48.9 
Lung 14 15.9 
Colorectal 9 10.2 
Upper GI 4 4.5 
Pancreatic 2 2.3 
Hepatobiliary 1 1.1 
Lymphoma 2 2.3 
Brain 2 2.3 
Breast 1 1.1 
Gynae/Ovarian/Peritoneal 4 4.5 
Prostate 1 1.1 
Urological (excluding prostate) 2 2.3 
Neuro-endocrine/carcinoid 2 2.3 
Mesothelioma 1 1.1 
Total 
 
88 100.0
 
  
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 Sh
eff
iel
d]
, [
Pe
ter
 B
ath
] a
t 0
2:0
5 0
3 J
an
ua
ry
 20
18
 
A
cc
ep
te
d 
M
an
us
cr
ip
t
Implementation of a metastatic malignancy of unknown primary origin service led by a 
palliative physician  
24 
 
Table 2 Demographics: 
 Pre-Pathway Post Pathway 
Age - mean 73.0 71.8 
       -median 76 72 
       -mode 66 68 
Gender  female % 54.0 55.3 
ECOG Performance status % 
0 
1 
2 
3 
4 
 
 
18.0 
66.0 
14.0 
0 
2.0 
 
13.6 
71.6 
12.5 
1.1 
1.1 
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Figure 1: Time from referral to death (days) according to whether final diagnosis 
was unknown primary or not 
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